The PCSK9 inhibitors: A novel therapeutic target enters clinical practice

American Health and Drug Benefits

Volumn 8, Issue 9, 2015, Pages 483-488

  Lepor, Norman E ^a   Kereiakes, Dean J ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Alirocumab; Bococizumab; Clinical guidelines; Clinical studies; Evolocumab; Familial hypercholesterolemia; LDL C hypothesis; Low density lipoprotein cholesterol; PCSK9 inhibitors; Statin treatment; Unmet needs

Indexed keywords

ALIROCUMAB; ANTILIPEMIC AGENT; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG APPROVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FAMILIAL HYPERLIPEMIA; FOLLOW UP; GENE MUTATION; HUMAN; INJECTION SITE REACTION; LIPID METABOLISM; META ANALYSIS (TOPIC); NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

EID: 84975769728     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-1118.
2. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-156.
3. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham study. Ann Intern Med. 1971;74:1-12.
4. O’Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
5. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407-420.
6. Greenough K, Cushing K. The Simon Broome criteria should be used to detect FH [published online December 2010]. Guidel Pract. www.guidelinesinpractice.co.uk/dec_10_greenough_fh_dec10#.Vkpr_aRdHWM. Accessed November 16, 2015.
7. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocu­mab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:554-561.
8. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
9. Kastelein JJP, Robinson JG, Farnier M, et al. Efficacy and safety of alirocu­mab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc Drugs Ther. 2014;28:281-289.
10. Roth EM, Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol. 2014;10:183-199.
11. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart J. 2015;169:906-915.e13.
12. Roth EM, Taskinen M-R, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol. 2014;176:55-61.
13. Cannon CP, Cariou B, Blom D, et al; for the ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186-1194.
14. Robinson JG, Farnier M, Krempf M, et al; for the ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499.
15. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. Poster presented at the American Heart Association Scientific Sessions 2014; November 15-19, 2014; Chicago, IL.
16. ClinicalTrials.gov. ODYSSEY Outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). www.clinicaltrials.gov/ct2/show/NCT01663402?term=ODYSSEY+OUTCOMES&rank=1. Accessed July 15, 2015.
17. Stroes E, Colquhoun D, Sullivan D, et al; for the GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541-2548.
18. Raal FJ, Stein EA, Dufour R, et al; for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo­controlled trial. Lancet. 2015;385:331-340.
19. Raal FJ, Honarpour N, Blom DJ, et al; for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:341-350.
20. ClinicalTrials.gov. The evaluation of bococizumab (PF-04950615;RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1). http://clinicaltrials.gov/ct2/show/NCT01975376?term=SPIRE-1&rank=1. Accessed July 15, 2015.
21. ClinicalTrials.gov. The evaluation of bococizumab (PF-04950615; RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2). http://clinicaltrials.gov/ct2/show/NCT01975389?term=SPIRE-2&rank=1. Accessed July 15, 2015.
22. Stone NJ, Robinson JG, Lichtenstein AH, et al; for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1-S45. Erratum in: Circulation. 2014;129(25):S46-S48.
23. Smith SC Jr, Grundy SM. 2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. J Am Coll Cardiol. 2014;64:601-612.
24. Cannon CP, Blazing MA, Giugliano RP, et al; for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387-2397.
25. Ray KK, Kastelein JJP, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960-968.
26. Robinson J, Farnier M, Chaudhari U, et al. Adverse events in patients with LDL-C <25 or <15 mg/dL on ≥2 consecutive visits in fourteen randomized trials of alirocumab. Presented at the 2015 International Symposium on Atherosclerosis; May 23-26, 2015; Amsterdam, the Netherlands.
27. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:40-51.